Literature DB >> 28536806

Increased Infiltration of Natural Killer and T Cells in Colorectal Liver Metastases Improves Patient Overall Survival.

Matteo Donadon1,2, Kelly Hudspeth3, Matteo Cimino1,2, Luca Di Tommaso4, Max Preti3, Paolo Tentorio3, Massimo Roncalli4, Domenico Mavilio5,6, Guido Torzilli7,8.   

Abstract

INTRODUCTION: Cancer heterogeneity and degree of intra-tumoral immune cells represent variables affecting overall survival (OS). The present study investigated the impact of natural killer (NK) and T cells infiltrating colorectal liver metastases (CLM) in patients undergoing hepatectomy after neoadjuvant chemotherapy.
METHODS: The frequencies of intra-tumoral, marginal, and peritumoral CD3+ T and NKp46+ NK cells were determined for 121 patients. OS was assessed in relation to prognostic factors.
RESULTS: At univariate analysis, several variables, including T and N of the primary tumor, metachronous CLM, radiological response, and higher density of intra-tumoral CD3+ T cell (>1%/mm2) and of NKp46+ NK cells (>1 cell/mm2), were associated with OS. Only increased frequencies of intra-tumoral CD3+ T cells (p = 0.005) and NKp46+ NK cells (p = 0.004) correlated with OS at multivariate analysis. The logistic regression revealed that metachronous CLM (OR = 2.781; p = 0.002), the use of an epidermal growth factor receptor inhibitor (OR = 3.891; p = 0.001), and radiological response (OR = 3.219; p = 0.001) were associated with higher infiltration of these cells.
CONCLUSIONS: High frequencies of NK and T cells in response to chemotherapy predict OS in CLM patients. These findings provide important insights that can help physicians to choose the best treatment option and adopt more predictive follow-up strategies for patients with CLM.

Entities:  

Keywords:  Chemotherapy; Colorectal liver metastases; Immune response to colorectal liver metastases; Natural killer cells; T cells

Mesh:

Substances:

Year:  2017        PMID: 28536806     DOI: 10.1007/s11605-017-3446-6

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  36 in total

1.  Cure model survival analysis after hepatic resection for colorectal liver metastases.

Authors:  Alessando Cucchetti; Alessandro Ferrero; Matteo Cescon; Matteo Donadon; Nadia Russolillo; Giorgio Ercolani; Giacomo Stacchini; Federico Mazzotti; Guido Torzilli; Antonio Daniele Pinna
Journal:  Ann Surg Oncol       Date:  2014-11-15       Impact factor: 5.344

2.  Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.

Authors:  Scott Kopetz; George J Chang; Michael J Overman; Cathy Eng; Daniel J Sargent; David W Larson; Axel Grothey; Jean-Nicolas Vauthey; David M Nagorney; Robert R McWilliams
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

3.  T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases.

Authors:  Steven C Katz; Venu Pillarisetty; Zubin M Bamboat; Jinru Shia; Cyrus Hedvat; Mithat Gonen; William Jarnagin; Yuman Fong; Leslie Blumgart; Michael D'Angelica; Ronald P DeMatteo
Journal:  Ann Surg Oncol       Date:  2009-07-01       Impact factor: 5.344

Review 4.  Epidermal growth factor receptor targeting in cancer.

Authors:  John Mendelsohn; Jose Baselga
Journal:  Semin Oncol       Date:  2006-08       Impact factor: 4.929

5.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

Authors:  Y Naito; K Saito; K Shiiba; A Ohuchi; K Saigenji; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

6.  Survival and the immune response in patients with carcinoma of the colorectum.

Authors:  A K House; A G Watt
Journal:  Gut       Date:  1979-10       Impact factor: 23.059

7.  Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients.

Authors:  Myrddin Rees; Paris P Tekkis; Fenella K S Welsh; Thomas O'Rourke; Timothy G John
Journal:  Ann Surg       Date:  2008-01       Impact factor: 12.969

8.  The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.

Authors:  Julie M Roda; Trupti Joshi; Jonathan P Butchar; Jaclyn W McAlees; Amy Lehman; Susheela Tridandapani; William E Carson
Journal:  Clin Cancer Res       Date:  2007-10-25       Impact factor: 12.531

9.  CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study.

Authors:  Luigi Laghi; Paolo Bianchi; Elena Miranda; Emanuela Balladore; Veronica Pacetti; Fabio Grizzi; Paola Allavena; Valter Torri; Alessandro Repici; Armando Santoro; Alberto Mantovani; Massimo Roncalli; Alberto Malesci
Journal:  Lancet Oncol       Date:  2009-08-03       Impact factor: 41.316

10.  Natural killer activity of human liver-derived lymphocytes in various liver diseases.

Authors:  K Hata; D H Van Thiel; R B Herberman; T L Whiteside
Journal:  Hepatology       Date:  1991-09       Impact factor: 17.425

View more
  31 in total

1.  Response to: "Liver Resection and Role of Extended Cytology and Histology".

Authors:  Luca Vigano; Guido Torzilli
Journal:  J Gastrointest Surg       Date:  2019-03-18       Impact factor: 3.452

Review 2.  Innate and acquired immune surveillance in the postdissemination phase of metastasis.

Authors:  Hugo Gonzalez; Isabella Robles; Zena Werb
Journal:  FEBS J       Date:  2017-11-24       Impact factor: 5.542

Review 3.  Hepatobiliary surgeons meet immunologists: the case of colorectal liver metastases patients.

Authors:  Matteo Donadon; Nina Cortese; Federica Marchesi; Matteo Cimino; Alberto Mantovani; Guido Torzilli
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

4.  Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery.

Authors:  Luca Vigano; Cristiana Soldani; Barbara Franceschini; Matteo Cimino; Ana Lleo; Matteo Donadon; Massimo Roncalli; Alessio Aghemo; Luca Di Tommaso; Guido Torzilli
Journal:  J Gastrointest Surg       Date:  2019-01-31       Impact factor: 3.452

Review 5.  Immune regulation and anti-cancer activity by lipid inflammatory mediators.

Authors:  Saraswoti Khadge; John Graham Sharp; Timothy R McGuire; Geoffrey M Thiele; Paul Black; Concetta DiRusso; Leah Cook; Lynell W Klassen; James E Talmadge
Journal:  Int Immunopharmacol       Date:  2018-11-14       Impact factor: 4.932

Review 6.  Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer.

Authors:  Carolina Mendonça Gorgulho; Anuradha Krishnamurthy; Anastasia Lanzi; Jérôme Galon; Franck Housseau; Ramon Kaneno; Michael T Lotze
Journal:  J Immunother       Date:  2021 Feb-Mar 01       Impact factor: 4.912

Review 7.  Liver Immune Microenvironment and Metastasis from Colorectal Cancer-Pathogenesis and Therapeutic Perspectives.

Authors:  Xuezhen Zeng; Simon E Ward; Jingying Zhou; Alfred S L Cheng
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

8.  A five-gene signature is a prognostic biomarker in pan-cancer and related with immunologically associated extracellular matrix.

Authors:  Chunlai Yu; Mingliang You; Peizhen Zhang; Sheng Zhang; Yuzhu Yin; Xiao Zhang
Journal:  Cancer Med       Date:  2021-06-14       Impact factor: 4.452

Review 9.  Surgical stress response and promotion of metastasis in colorectal cancer: a complex and heterogeneous process.

Authors:  Corina Behrenbruch; Carolyn Shembrey; Sophie Paquet-Fifield; Christina Mølck; Hyun-Jung Cho; Michael Michael; Benjamin N J Thomson; Alexander G Heriot; Frédéric Hollande
Journal:  Clin Exp Metastasis       Date:  2018-01-15       Impact factor: 4.510

10.  IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction.

Authors:  Nicholas J W Easom; Kerstin A Stegmann; Leo Swadling; Laura J Pallett; Alice R Burton; Dennis Odera; Nathalie Schmidt; Wei-Chen Huang; Giuseppe Fusai; Brian Davidson; Mala K Maini
Journal:  Front Immunol       Date:  2018-05-09       Impact factor: 8.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.